心力衰竭中的代谢-电生理学合:从双向脱到治疗性重新合
Hong Yu1, Shi-Yao Chang1, Xin Tian2
1Graduate School, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi Province, 330006, China.
Current heart failure reports
|November 29, 2025
概括
心脏电生理学和新陈代谢合失调会使心脏衰竭恶化. 将这种联系与新疗法准可能会改善心脏功能和患者的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 心力衰竭 (HF) 是一个主要的全球健康问题,其特点是渐进的心脏功能障碍.
- 心肌细胞电活动和能量代谢之间的相互作用对于维持心脏功能至关重要.
- 这些过程的功能障碍合有助于HF的进展.
研究的目的:
- 审查心力衰竭中被破坏的代谢电生理学合的作用.
- 根据这种结合,识别和总结基于HF的新兴治疗点.
主要方法:
- 关于心脏电生理学和高频代谢的当前研究的文献综述.
- 对针对电代谢合的治疗干预措施的临床前和临床研究的分析.
主要成果:
- 证据支持电代谢合在高频中发挥的关键作用.
- 目前针对电路或代谢途径的治疗方法显示出有效性.
- 基础研究证实了针对高温治疗的电代谢交叉声的概念.
结论:
- 恢复心脏新陈代谢和电生理学之间的整合是对HF的有希望的治疗策略.
- 诸如代谢调节器和线粒体向剂等干预措施显示出潜在的潜力.
- 针对电代谢合的综合方法可能会改善HF患者的治疗结果.
更多相关视频
相关概念视频
Heart Failure II: Pathophysiology
658
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
658
Heart Failure VI: Adjunct Therapies
228
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
228
Cardiomyopathy II: Dilated Cardiomyopathy
427
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
427
Pathophysiology of Heart Failure
2.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K
Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Cardiac Action Potential
5.5K
Cardiac action potentials are essential for proper heart function, enabling the rhythmic contractions needed for adequate blood circulation. Nodal cells and Purkinje fibers, specialized for electrical conduction, generate these action potentials.
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
5.5K


